Pharmacological strategies for lowering LDL cholesterol: statins and beyond (original) (raw)
National Cholesterol Education Program. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation106, 3143–3421 (2002).
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
Graham, I. et al. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil.14 (Suppl. 2), S1–S113 (2007). ArticlePubMed Google Scholar
Genest, J. et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can. J. Cardiol.25, 567–579 (2009). ArticleCASPubMedPubMed Central Google Scholar
Di Angelantonio, E. et al. for the Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA302, 1993–2000 (2009). ArticleCASPubMed Google Scholar
Sharrett, A. R. et al. for the Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation104, 1108–1113 (2001). ArticleCASPubMed Google Scholar
Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med.354, 1264–1272 (2006). ArticleCASPubMed Google Scholar
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
Cannon, C. P. et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350, 1495–1504 (2004). ArticleCASPubMed Google Scholar
Sever, P. S. et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicenter randomised controlled trial. Lancet361, 1149–1158 (2003). ArticleCASPubMed Google Scholar
Shepherd, J. et al. for the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360, 1623–1630 (2002). ArticleCASPubMed Google Scholar
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA288, 2998–3007 (2002).
Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004). ArticlePubMed Google Scholar
LaRosa, J. C. et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352, 1425–1435 (2005). ArticleCASPubMed Google Scholar
Pedersen, T. R. et al. for the IDEAL Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294, 2437–2445 (2005). ArticleCASPubMed Google Scholar
Smith, S. C., Jr. et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation113, 2363–2372 (2006). ArticlePubMed Google Scholar
Brunzell, J. D. et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol.51, 1512–1524 (2008). ArticlePubMed Google Scholar
Ridker, P. M. et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008). ArticleCASPubMed Google Scholar
Ridker, P. M. et al. for the JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet376, 333–339 (2010). ArticleCASPubMed Google Scholar
Jones, P. H. et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther.26, 1388–1399 (2004). ArticleCASPubMed Google Scholar
Pasternak, R. C. et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol.40, 567–572 (2002). ArticlePubMed Google Scholar
Arnaboldi, L. & Corsini, A. Do structural differences in statins correlate with clinical efficacy? Curr. Opin. Lipidol.21, 298–304 (2010). ArticleCASPubMed Google Scholar
Jones, P. H. et al. for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. J. Cardiol.92, 152–160 (2003). ArticleCASPubMed Google Scholar
Saito, Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc. Health Risk. Manag.5, 921–936 (2009). ArticleCASPubMedPubMed Central Google Scholar
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med.353, 238–248 (2005). ArticleCASPubMed Google Scholar
Fellström, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med.360, 1395–1407 (2009). ArticlePubMedCAS Google Scholar
Kjekshus, J. et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med.357, 2248–2261 (2007). ArticleCASPubMed Google Scholar
GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet372, 1231–1239 (2008).
Carlson, L. A. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med.258, 94–114 (2005). ArticleCASPubMed Google Scholar
Bays, H. E. & Ballantyne, C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr. Opin. Lipidol.20, 467–476 (2009). ArticleCASPubMed Google Scholar
Corsini, A., Windler, E. & Farnier, M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur. J. Cardiovasc. Prev. Rehabil.16, 1–9 (2009). ArticlePubMed Google Scholar
Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R. & Bailey, W. L. Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin. Ther.29, 74–83 (2007). ArticleCASPubMed Google Scholar
Bays, H. E., Davidson, M., Jones, M. R. & Abby, S. L. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am. J. Cardiol.97, 1198–1205 (2006). ArticleCASPubMed Google Scholar
Hou, R. & Goldberg, A. C. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol. Metab. Clin. North Am.38, 79–97 (2009). ArticleCASPubMed Google Scholar
Sudhop, T. et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation106, 1943–1948 (2002). ArticleCASPubMed Google Scholar
Ballantyne, C. M. et al. for the EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am. J. Cardiol.99, 673–680 (2007). ArticleCASPubMed Google Scholar
Califf, R. M. et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am. Heart J.159, 705–709 (2010). ArticlePubMed Google Scholar
Davidson, M. H. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf.5, 145–156 (2006). ArticleCASPubMed Google Scholar
Goldberg, A. C. et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am. J. Cardiol.103, 515–522 (2009). ArticleCASPubMed Google Scholar
Staels, B. et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation98, 2088–2093 (1998). ArticleCASPubMed Google Scholar
Jones, P. H. et al. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am. J. Cardiovasc. Drugs10, 73–84 (2010). ArticleCASPubMed Google Scholar
Manninen, V. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation85, 37–45 (1992). ArticleCASPubMed Google Scholar
Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med.341, 410–418 (1999). ArticleCASPubMed Google Scholar
BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation102, 21–27 (2000).
IELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study). Lancet366, 1849–1861 (2005).
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med.362, 1563–1574 (2010).
Harris, W. S. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J. Lipid Res.30, 785–807 (1989). ArticleCASPubMed Google Scholar
Davidson, M. H. et al. for the COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther.29, 1354–1367 (2007). ArticleCASPubMed Google Scholar
McKenney, J. M. & Sica, D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am. J. Health Syst. Pharm.64, 595–605 (2007). ArticleCASPubMed Google Scholar
Yokoyama, M. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet369, 1090–1098 (2007). ArticleCASPubMed Google Scholar
Brown, M. S., Hobbs, H. H. & Goldstein, J. L. in Metabolic and Molecular Bases of Inherited Disease (eds Scriver, C. R., Sly, W. S. & Childs, B.) Ch. 120 (McGraw-Hill, New York, 2001) [online], (2001). Google Scholar
Myant, N. B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis104, 1–18 (1993). ArticleCASPubMed Google Scholar
Tarugi, P. et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis195, e19–e27 (2007). ArticleCASPubMed Google Scholar
Sankatsing, R. R. et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol.25, 1979–1984 (2005). ArticleCASPubMed Google Scholar
Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem.270, 1628–1644 (2003). ArticleCASPubMed Google Scholar
Yu, R. Z. et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos.35, 460–468 (2007). ArticleCASPubMed Google Scholar
Crooke, R. M. et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res.46, 872–884 (2005). ArticleCASPubMed Google Scholar
Merki, E. et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation118, 743–753 (2008). ArticleCASPubMed Google Scholar
Yu, R. Z. et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol.77, 910–919 (2009). ArticleCASPubMed Google Scholar
Kastelein, J. J. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation114, 1729–1735 (2006). ArticleCASPubMed Google Scholar
Yu, R. Z. et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet.48, 39–50 (2009). ArticleCASPubMed Google Scholar
Akdim, F. et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J. Am. Coll. Cardiol.55, 1611–1618 (2010). ArticleCASPubMed Google Scholar
Rader, D. J., Cohen, J. & Hobbs, H. H. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest.111, 1795–1803 (2003). ArticleCASPubMedPubMed Central Google Scholar
Akdim, F. et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol.105, 1413–1419 (2010). ArticleCASPubMed Google Scholar
Raal, F. J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet375, 998–1006 (2010). ArticleCASPubMed Google Scholar
Kane, J. P. & Havel, R. J. in Metabolic and Molecular Bases of Inherited Disease (eds Scriver, C. R., Sly, W. S. & Childs, B.) Ch. 115 (McGraw-Hill, New York, 2001) [online], (2001). Google Scholar
Fazio, S. & Linton, M. F. in Clinical Lipidology: a Companion to Braunwald's Heart Disease (ed. Ballantyne, C. M.) 11–25 (Saunders, Philadelphia, 2008). Google Scholar
Wetterau, J. R. et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science258, 999–1001 (1992). ArticleCASPubMed Google Scholar
Sharp, D. et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinemia. Nature365, 65–69 (1993). ArticleCASPubMed Google Scholar
Rader, D. J. & Brewer, H. B. Jr. Abetalipoproteinemia: new insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. JAMA270, 865–869 (1993). ArticleCASPubMed Google Scholar
Wetterau, J. R. et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science282, 751–754 (1998). ArticleCASPubMed Google Scholar
Liao, W., Hui, T. Y., Young, S. G. & Davis, R. A. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J. Lipid Res.44, 978–985 (2003). ArticleCASPubMed Google Scholar
Cuchel, M. et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med.356, 148–156 (2007). ArticleCASPubMed Google Scholar
Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J. & Rader, D. J. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med.5, 497–505 (2008). ArticleCASPubMed Google Scholar
Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet.37, 161–165 (2005). ArticleCASPubMed Google Scholar
Berge, K. E., Ose, L. & Leren, T. P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol.26, 1094–1100 (2006). ArticleCASPubMed Google Scholar
Kotowski, I. K. et al. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet.78, 410–422 (2006). ArticleCASPubMedPubMed Central Google Scholar
Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet.79, 514–523 (2006). ArticleCASPubMedPubMed Central Google Scholar
Dubuc, G. et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.24, 1454–1459 (2004). ArticleCASPubMed Google Scholar
Chan, J. C. et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl Acad. Sci. USA106, 9820–9825 (2009). ArticleCASPubMedPubMed Central Google Scholar
Abifadel, M. et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin. Ther. Pat.20, 1547–1571 (2010). ArticleCASPubMed Google Scholar
Ni, Y. G. et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9)-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces free circulating PCSK9 and LDL-cholesterol. J. Lipid Res.52, 78–86 (2011). ArticleCASPubMedPubMed Central Google Scholar
Graham, M. J. et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res.48, 763–767 (2007). ArticleCASPubMed Google Scholar
Jepsen, J. S., Sørensen, M. D. & Wengel, J. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Oligonucleotides14, 130–146 (2004). ArticleCASPubMed Google Scholar
Gupta, N. et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One5, e10682 (2010). ArticlePubMedPubMed CentralCAS Google Scholar
Santaris Pharma A/S. Santaris Pharma A/S advances RNA-targeted drug development candidate against PCSK9, an important new target for the treatment of high cholesterol [online], (2010).
Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature411, 494–498 (2001). ArticleCASPubMed Google Scholar
Frank-Kamenetsky, M. et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA105, 11915–11920 (2008). ArticleCASPubMedPubMed Central Google Scholar
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA231, 360–381 (1975).
Angelin, B. & Rudling, M. Lipid lowering with thyroid hormone and thyromimetics. Curr. Opin. Lipidol.21, 499–506 (2010). ArticleCASPubMed Google Scholar
Baxter, J. D. & Webb, P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat. Rev. Drug Discov.8, 308–320 (2009). ArticleCASPubMed Google Scholar
Ladenson, P. W. et al. Use of the thyroid hormone analog eprotirome in statin-treated dyslipidemia. N. Engl. J. Med.362, 906–916 (2010). ArticleCASPubMed Google Scholar
Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science232, 34–47 (1986). ArticleCASPubMed Google Scholar
Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet.34, 154–156 (2003). ArticleCASPubMed Google Scholar
Maxwell, K. N. & Breslow, J. L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl Acad. Sci. USA.101, 7100–7105 (2004). ArticleCASPubMedPubMed Central Google Scholar
Regeneron. Regeneron provides initial data on two antibody product candidates [online], (2010).
Luo, Y. et al. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J. Lipid Res.50, 1581–1588 (2009). ArticleCASPubMedPubMed Central Google Scholar
Steinberg, D. & Witztum, J. L. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc. Natl Acad. Sci. USA106, 9, 546–9, 547 (2009). Article Google Scholar
ISIS Pharmaceuticals. Drugs in development [online], (2010).
U. S. NIH. Safety study of BMS-844421 for treatment of hypercholesterolemia [online], (2011).
Adnexus. Our science. Adnectin product class [online], (2008).